Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Precision BioSciences in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.19) per share for the quarter, down from their prior forecast of ($0.58). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($3.47) EPS, FY2027 earnings at ($1.55) EPS, FY2028 earnings at ($0.75) EPS and FY2029 earnings at ($0.95) EPS.
Several other equities research analysts have also recently commented on DTIL. JonesTrading restated a “buy” rating and set a $30.00 price target on shares of Precision BioSciences in a research note on Friday, April 17th. Oppenheimer began coverage on shares of Precision BioSciences in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price objective on the stock. Wall Street Zen downgraded shares of Precision BioSciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.25.
Precision BioSciences Stock Down 1.6%
Precision BioSciences stock opened at $7.30 on Friday. The stock has a 50 day moving average of $7.44 and a two-hundred day moving average of $6.44. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $9.62. The stock has a market capitalization of $201.48 million, a price-to-earnings ratio of -2.61 and a beta of 1.27. The company has a current ratio of 12.82, a quick ratio of 12.82 and a debt-to-equity ratio of 0.50.
Precision BioSciences (NASDAQ:DTIL – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%.
Institutional Investors Weigh In On Precision BioSciences
Several institutional investors have recently made changes to their positions in DTIL. HBK Sorce Advisory LLC acquired a new position in shares of Precision BioSciences during the 4th quarter worth $38,000. Engineers Gate Manager LP acquired a new stake in shares of Precision BioSciences in the fourth quarter valued at about $43,000. Occudo Quantitative Strategies LP purchased a new stake in Precision BioSciences during the fourth quarter worth about $52,000. Miller Financial Services LLC boosted its holdings in Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after buying an additional 5,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Precision BioSciences during the third quarter worth about $84,000. 37.99% of the stock is currently owned by hedge funds and other institutional investors.
Precision BioSciences Company Profile
Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.
Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.
Featured Articles
- Five stocks we like better than Precision BioSciences
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
